

Poster presentation

Open Access

## N-terminal fragment of proBNP is a marker of high cardiac output cardiomyopathy evaluated by CMR in thalassemia syndromes

Antonella Meloni<sup>1</sup>, Alessia Pepe<sup>1</sup>, Luc Zyw<sup>1</sup>, Vincenzo Positano<sup>1</sup>, Maria Chiara Dell'Amico<sup>1</sup>, Concetta Prontera<sup>1</sup>, Claudio Passino<sup>1</sup>, Filomena Fabrizio<sup>1</sup>, Maria Antonietta Romeo<sup>2</sup>, Michele Ein<sup>1</sup> and Massimo Lombardi<sup>\*1</sup>

Address: <sup>1</sup>G Monasterio Foundation and Institute of Clinical Physiology, CNR, Pisa, Italy and <sup>2</sup>Azienda Policlinico, Catania, Italy

\* Corresponding author

from 13th Annual SCMR Scientific Sessions  
Phoenix, AZ, USA. 21-24 January 2010

Published: 21 January 2010

*Journal of Cardiovascular Magnetic Resonance* 2010, **12**(Suppl 1):P266 doi:10.1186/1532-429X-12-S1-P266

This abstract is available from: <http://jcmr-online.com/content/12/S1/P266>

© 2010 Meloni et al; licensee BioMed Central Ltd.

### Introduction

In thalassemia patients heart failure remains the main cause of mortality. High cardiac output state due to chronic anaemia is a significant determinant of cardiomyopathy, in particular in thalassemia intermedia (TI) patients (a moderate form, not transfusion dependent). Hypoxia and volume overload are known stimuli for plasma N-terminal fragment of proBNP (NT-proBNP) raise. Nevertheless, NT-proBNP role in clinical management of thalassemia patients has not been fully investigated.

### Purpose

Aim of our study was to assess the role of NT-proBNP assay in a large prospective cohort of thalassemia patients, evaluated by cardiovascular magnetic resonance (CMR).

### Methods

215 thalassemia patients (39 TI, age  $38 \pm 12$  years, 51% females) and 176 thalassemia major patients (TM, age  $30 \pm 9$  years, 54% females) underwent consecutively CMR (1.5 T) and blood sampling for plasma assay of NT-proBNP. Myocardial iron overload was assessed using a multislice multiecho T2\* approach able to provide the global T2\* value in the left ventricle. Cine sequences were obtained to quantify biventricular morphological and functional parameters. RV and LV volumes and ejection

fraction (EF) were evaluated by a semi-automatic software (Mass Plus, Leiden, NL).

### Results

NT-proBNP levels were comparable in TI and TM patients ( $139 \pm 146$  ng/L versus  $108 \pm 122$  ng/L;  $P = \text{NS}$ ). Mean haemoglobin levels ( $P < 0.0001$ ) and myocardial iron overload ( $P = 0.001$ ) were significantly lower in TI than in TM patients. Left end-diastolic volume ( $P < 0.0001$ ) and mass indexes ( $P = 0.002$ ), right ejection fraction ( $P < 0.0001$ ) and biatrial area indexes ( $P = 0.006$ ) were significantly higher in TI vs. TM patients. In TI patients NT-proBNP was negatively associated with mean haemoglobin levels ( $r = -0.6$ ,  $P = 0.008$ ) and positively with left and right atrial area indexes ( $r = 0.6$ ,  $P = 0.001$  and  $r = 0.4$ ,  $P = 0.007$ , respectively), left and right end diastolic volume indexes ( $r = 0.5$ ,  $P = 0.003$  and  $r = 0.3$ ,  $P = 0.04$ , respectively) and left ventricular mass index ( $r = 0.4$ ,  $P = 0.007$ ). In TM patients no significant correlation was found between NT-proBNP levels and morphological biventricular parameters. In both groups no significant correlation was found between NT-proBNP levels and myocardial iron overload.

### Conclusion

Hypoxia and volume overload due to chronic anaemia, more pronounced in TI patients, justify the correlation

between NT-proBNP and high cardiac output-related findings in TI patients. These data suggest a) a potential routine use of NT-proBNP as marker of high cardiac output cardiomyopathy in the anaemic thalassemia population; b) to reconsider the current haematological/transfusional management in TI patients.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

